KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Retained Earnings (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Retained Earnings readings, the most recent being $38000.0 for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 95.87% to $38000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $38000.0, a 95.87% decrease, with the full-year FY2025 number at $38000.0, down 95.87% from a year prior.
  • Retained Earnings hit $38000.0 in Q4 2025 for Biocryst Pharmaceuticals, down from $1.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $2.3 million in Q3 2024 to a low of -$1.8 billion in Q1 2025.
  • Median Retained Earnings over the past 5 years was $32000.0 (2022), compared with a mean of -$617.9 million.
  • Biggest five-year swings in Retained Earnings: surged 5800.0% in 2021 and later crashed 6466096.15% in 2023.
  • Biocryst Pharmaceuticals' Retained Earnings stood at $177000.0 in 2021, then tumbled by 85.31% to $26000.0 in 2022, then crashed by 6466096.15% to -$1.7 billion in 2023, then soared by 100.05% to $921000.0 in 2024, then plummeted by 95.87% to $38000.0 in 2025.
  • The last three reported values for Retained Earnings were $38000.0 (Q4 2025), $1.1 million (Q3 2025), and -$1.8 billion (Q2 2025) per Business Quant data.